Related and Nonrelated Parties [Axis] Related Party [Member] Class of Stock [Axis] Series C 9% Convertible Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series F Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Noncontrolling Interest [Member] Business Combination [Axis] Viral Clear[Member] Investment, Name [Axis] BioSig AI Sciences, Inc. [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] One Customer [Member] Customer One [Member] Accounts Receivable [Member] Customer Two [Member] Customer Three [Member] Geographical [Axis] UNITED STATES CANADA Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Restricted Stock [Member] Exchangeable Shares [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Furniture and Fixtures [Member] Testing/Demo Equipment [Member] Leasehold Improvements [Member] Finite-Lived Intangible Assets by Major Class [Axis] Trade Names [Member] Developed Technology Rights [Member] Legal and Compliance Frame Work [Member] Patents [Member] Sale Leaseback Transaction, Description [Axis] Contract Assets Current [Member] Contract Assets Noncurrent [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Title and Position [Axis] Chief Executive Officer [Member] Investor [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Purchase Agreement [Member] Statistical Measurement [Axis] Maximum [Member] Legal Entity [Axis] H.C Wainwright And Co LLC [Member] Sales Agreement [Member] Market Offering Agreement [Member] Minimum [Member] Plan Name [Axis] 2023 Long-Term Incentive Plan [Member] Measurement Input Type [Axis] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input Dividend Payout [Member] Measurement Input, Expected Term [Member] Key Consultant [Member] 2019 Long-Term Incentive Plan [Member] ViralClear Pharmaceuticals, Inc. [Member] BioSig AI Sciences, Inc. [Member] Exercise Price Range [Axis] Options Under 9.99 [Member] Options 10.00 To 19.99 [Member] Options 20.00 To 49.99 [Member] Options 50.00 To 69.99 [Member] Warrants At 0.3000 [Member] Warrants At 0.9547 [Member] Warrants At 1.7800 [Member] Warrants At 2.3875 [Member] Warrants At 3.3640 [Member] Warrants At 4.0660 [Member] Warrants At 4.4550 [Member] Warrants At 4.4660 [Member] Warrants At 4.6626 [Member] Warrants At 4.9252 [Member] Warrants At 4.9290 [Member] Warrants At 5.1358 [Member] Warrants At 7.1810 [Member] Warrants At 7.5020 [Member] Warrants At 7.9630 [Member] Warrants At 9.0000 [Member] Warrants At 9.5960 [Member] Warrants At 10.0992 [Member] Warrants At 10.2600 [Member] Warrants At 10.4678 [Member] Warrants At 11.3000 [Member] Warrants At 13.2800 [Member] Warrants At 14.0000 [Member] Warrants At 48.0000 [Member] Warrants At 61.6000 [Member] Range One [Member] Consolidated Entities [Axis] 2017 Know-How License Agreement [Member] EP Software Agreement [Member] Tools Agreement [Member] Viral Clear Patent Agreement [Member] Trek Therapeutics [Member] First Country [Member] Second Country [Member] TriView Capital Ltd [Member] Subscription Agreement [Member] Share Purchase Agreement [Member] Settlement Agreement [Member] Streamex Exchange Corporation [Member] Securitization Platform [Member] Blockchain Integration [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Fair Value, Nonrecurring [Member] Developed Technology [Member] Financial Instrument [Axis] Trade Name [Member] Valuation Approach and Technique [Axis] Relief from Royalty Method [Member] Royalty Rate [Member] Discount Rate [Member] Income Tax Rate [Member] Tax Amortization Period [Member] Multi Period Excess Earnings Method [Member] Revenue Growth Rates [Member] Contributory Assets Charge [Member] Obsolece [Member] Earnings Before Interest and Taxes [Member] Cost Approach [Member] Replacement Cost Growth Rate [Member] After Tax Rate of Return [Member] Useful Life [Member] Valuation Technique, Discounted Cash Flow [Member] Terminal Growth Rate [Member] Capitalization Rate [Member] Segments [Axis] Corporate Segment [Member] Mr Amato [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Debt Instrument [Axis] Senior Secured Convertible Debentures [Member] Two Secured Convertible Debentures [Member] Standby Equity Purchase Agreement [Member] Investors [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS Current assets: Cash Accounts receivable, net Sales tax receivable Due from related party Net investment in leases, short term Prepaid expenses and vendor deposits Total current assets Non-current assets: Property and equipment, net Right-to-use assets, net Net investment in leases, long term Other assets Intangible assets, net Goodwill Total non-current assets Total assets LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable and accrued expenses, including $466 and $19 to related parties as of June 30, 2025 and December 31, 2024, respectively Derivative liability Dividends payable Lease liability, short term Total current liabilities Total liabilities Commitments and contingencies (Note 12) Mezzanine Equity Redeemable Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; (liquidation preference of $105; cumulative dividends payable of $115 and $110 as of June 30, 2025 and December 31, 2024, respectively) Stockholders’ deficit: Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. Common stock, $0.001 par value, authorized 200,000,000 shares, 30,793,135 and 17,239,096 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively Additional paid-in-capital Accumulated other comprehensive income Accumulated deficit Total stockholders’ deficit attributable to BioSig Technologies, Inc. Non-controlling interest Total stockholders’ deficit Total liabilities, mezzanine equity and stockholders’ deficit Statement [Table] Statement [Line Items] Accounts payable and accrued expenses, related parties Temporary equity, par value Temporary equity, stated value Temporary equity, shares authorized Temporary equity, shares issued Temporary equity, shares outstanding Liquidation preference Cumulative dividends Preferred stock, par value Preferred stock, shares authorized Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Research and development General and administrative Impairment of long term assets Depreciation and amortization  Total operating expenses Loss from operations Other income (expense): Interest income, net Gain (loss) on settlement and forgiveness of debt Other income (expense), net: Total other income (expense), net Loss before income taxes Income taxes (benefit) Net loss Non-controlling interest Net loss attributable to BioSig Technologies, Inc. Preferred stock dividend Preferred stock deemed dividend Net loss attributed to BioSig Technologies, Inc. Common Shareholders Net loss per common share, basic Net loss per common share, diluted Weighted average number of common shares outstanding, basic Weighted average number of common shares outstanding, diluted Comprehensive Income (Loss): Foreign currency translation adjustments Total comprehensive loss Comprehensive (loss) income attributable to non-controlling interest Comprehensive (loss) income attributable to BioSig Technologies, Inc. Balance Balance, shares Common stock issued for services Common stock issued for services, shares Exercise of warrants Exercise of warrants, shares Stock based compensation Stock based compensation, shares Sale of common stock under at-the- market offering, net of transaction costs Sale of common stock under-at-the market offering, net of transaction costs, shares Sale of common stock and warrants Sale of common stock and warrants, shares Common stock issued to settle accounts payable Stock issued as extinguishment of debt, shares Preferred stock dividend Net loss Common stock cancelled Common stock cancelled, shares Other comprehensive income Sale of common stock and warrants, net transactional costs Sale of common stock and warrants, net transactional costs, shares Accretion of deemed preferred stock dividend Deemed preferred stock dividend Common stock issued in exchange for principal and accrued interest on a note payable Common stock issued in exchange for principal and accrued interest on a note payable, shares Sale of common stock and warrants, net transactional costs Sale of common stock and warrants, net transactional costs, shares Stock issued as forgiveness of accounts payable Stock issued as forgiveness of accounts payable, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to cash used in operating activities: Gain on settlement of debt Non-cash lease expense Common stock issued for services rendered Stock based compensation Allowance for credit losses on accounts receivable Impairment of long-term assets Changes in operating assets and liabilities: Accounts receivable Lease receivables Sales tax receivable Employee advances Unbilled revenue Prepaid expenses Customer deposits Accounts payable and accrued expenses Operating lease liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Business acquisition, net of cash acquired Net cash provided by investing activity CASH FLOWS FROM FINANCING ACTIVITIES: Sale of common stock under at-the- market offering, net of transaction costs Sale of common stock and warrants Proceeds from issuance of related party note payable Proceeds from sale of common stock and warrants, net of issuance costs Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase in cash and cash equivalents Cash, beginning of the period Cash, end of the period Supplemental disclosures of cash flow information: Cash paid during the period for interest Cash paid during the period for income taxes Non cash investing and financing activities: Recognition of derivative liability as part of business combination (non-cash) Recognition of assets acquired as part of business combination (non-cash) Recognition of liabilities assumed as part of business combination (non-cash) Common stock issued in settlement of accounts payable Dividend payable on preferred stock charged to additional paid-in-capital Series C convertible preferred stock deemed dividend Common stock issued for conversion of note payable and accrued interest Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] GOODWILL AND INTANGIBLE ASSETS Right To Use Assets And Lease Liability RIGHT TO USE ASSETS AND LEASE LIABILITY Lease Receivables LEASE RECEIVABLES Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Equity [Abstract] STOCKHOLDER EQUITY OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Noncontrolling Interest [Abstract] NON-CONTROLLING INTEREST Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] BUSINESS ACQUISITION Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Segment Reporting [Abstract] SEGMENT REPORTING Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principals of Consolidation Use of Estimates Business Acquisition Intangible Assets Goodwill Derivative Liability Revenue and Accounts Receivable Allowance for Credit losses Concentrations of Credit Risk Foreign Currency Translations and Transactions Concentration of Assets Net Income (loss) Per Common Share Stock Based Compensation Recent Accounting Pronouncements SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF CARRYING AMOUNT OF GOODWILL SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS SCHEDULE OF RIGHT TO USE ASSETS SCHEDULE OF LEASE LIABILITY SCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS SCHEDULE OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF INFORMATION RELATED TO WARRANTS SCHEDULE OF WARRANT ACTIVITY SCHEDULE OF RESTRICTED STOCK ACTIVITY SCHEDULE OF NON-CONTROLLING INTEREST SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED SCHEDULE OF UNAUDITED PRO FORMA CONSOLIDATED RESULTS OF REVENUE AND NET LOSS SUMMARY OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS SUMMARY OF UNOBSERVABLE INPUTS SUMMARY OF FAIR VALUE MEASUREMENTS DERIVATIVE LIABILITY SCHEDULE OF SEGMENT REPORTING Restructuring Cost [Table] Restructuring Cost and Reserve [Line Items] Sale of stock, shares Sale of stock, value Shares issued for acquisition Ownership percentage Equity method investment, ownership percentage Working capital deficit Net cash operating activities Totals Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] Fair value derivative liability Concentration risk, percentage Allowance for doubtful accounts Bad debt expenses FDIC limits Cash held in deposits Assets Consolidated asset percentage Goodwill and intangible assets Cash Other Receivables Prepaid expense Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Total Less accumulated depreciation Property and equipment, net Impairment of long lived assets Depreciation Goodwill, beginning Acquisition Impairment Foreign currency translation adjustment Goodwill, ending Intangible Asset, Finite-Lived [Table] Finite-Lived Intangible Assets [Line Items] Total Accumulated amortization Intangible assets, net Remainder of 2025 2026 2027 2028 2029 Thereafter Goodwill impairment Amortization of Debt Issuance Costs Schedule Of Right To Use Assets Right to use asset Less accumulated amortization Right to use assets, net Schedule Of Lease Liability Total lease liability Less: short term portion Long term portion Year ended December 31, 2025 Total Less: Present value discount Lease liability Operating lease, expense Operating lease, description Operating lease expense Sale Leaseback Transaction [Table] Sale Leaseback Transaction [Line Items] Balance Recognized in Revenue Invoiced to Customer Interest Earned Unguaranteed Residual Assets Balance Operating leases, rent expense Operating lease, term of contract Operating lease, renewal term Lessor sales type lease discount rate Accrued accounting and legal Accrued reimbursements and travel Accrued consulting Accrued finders fee Accrued research and development expenses Accrued marketing Accrued office and other Accrued settlement expense Accrued payroll Accounts payable and accrued expenses Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock, par or stated value per share (in dollars per share) Preferred stock, shares outstanding Preferred stock, shares issued Dividends payable Common Stock, Shares Authorized Common Stock, Shares, Outstanding Reverse stock split Number of shares issued Settlement and extinguishment of accounts payable Stock Issued During Period, Value, Issued for Services Number of shares issued Number of shares exercised Stock issued during period, shares, new issues Number of shares cancelled Derivative Liability, Subject to Master Netting Arrangement, before Offset Sold to investors Class of Warrant or Right, Number of Securities Called by Warrants or Rights Purchase price of warrants Exercise price, warrants Sale of stock, consideration received on transaction Sale of Stock, Price Per Share Debt Instrument, Increase, Accrued Interest Shares issued, price per share Class of warrant or rights granted Proceeds from issuance or sale of equity Stock issued during period, shares, new issues Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Options Outstanding, Exercise Price Number of Options Outstanding Number of Options Outstanding Weighted Average Remaining Life Number of Options Outstanding Options Exercisable Options Outstanding, Exercise Price Outstanding shares Weighted Average Exercise Price Outstanding Weighted-Average Remaining Contractual Term Outstanding Aggregate Intrinsic Value Issued Weighted Average Exercise Price Issued Weighted-Average Remaining Contractual Term, Issued Forfeited/expired Weighted Average Exercise Price Forfeited/expired Outstanding shares Weighted Average Exercise Price Outstanding Outstanding Aggregate Intrinsic Value Outstanding shares Exercisable Weighted Average Exercise Price Exercisable Weighted-Average Remaining Contractual Term Outstanding Exercisable Aggregate Intrinsic Value Subsidiary or Equity Method Investee, Sale of Stock [Table] Subsidiary or Equity Method Investee [Line Items] Exercise price Number Outstanding Expiration date Outstanding shares Weighted-Average Exercise Price,beginning Weighted-Average Remaining Contractual Term, Outstanding Aggregate Intrinsic Value Issued Weighted-Average Exercise Price Issued Weighted-Average Remaining Contractual Term, Issued Forfeited/expired Weighted Average Exercise Price Forfeited/expired Outstanding Aggregate Intrinsic Value, Forfeited/expired Exercised Weighted-Average Exercise Price Expired Outstanding Aggregate Intrinsic Value, Exercised Outstanding shares Weighted-Average Exercise Price ending Weighted-Average Remaining Contractual Term, Outstanding Weighted-Average Remaining Contractual Term, Outstanding Warrants Vested and expected to vest, Shares Weighted-Average Exercise Price Vested and expected to vest Weighted-Average Remaining Contractual Term Vested and expected to ves Warrants Vested and expected to vest, Aggregate Intrinsic Value Warrants Exercisable, Shares Weighted-Average Exercise Price Exercisable Weighted-Average Remaining Contractual Term Exercisable Warrants Exercisable, Aggregate Intrinsic Value Weighted-Average Exercise Price, Forfeited/expired Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Restricted shares issued, beginning balance Granted Vested and issued Forfeited Restricted shares issued, ending balance Vested restricted shares Unvested restricted shares Vested restricted shares Total Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock, capital shares reserved for future issuance Exercise price Options vesting fair value Options vesting fair value Restricted stock, unamortized Weighted average period term Employee Benefits and Share-Based Compensation Derivative liability Derivative liability, measurement input, expected life Warrants to purchase shares Warrants outstanding exercise price Shares of its common stock, warrants Stock Issued During Period, Shares, New Issues Stock price Restricted common stock Restricted common stock, value Services, shares Services, value Share-based payment arrangement, noncash expense Shares remaining Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Net income (loss) Average Non-Controlling interest percentage of profit/losses Net loss attributable to non-controlling interest Balance, January 1, 2024 Net income (loss) attributable to non-controlling interest Balance, June 30, 2024 Majority interest Loss Contingencies [Table] Loss Contingencies [Line Items] Royalty percentage of net sales Accounts payable due Royalty payments Commitment amount Payments for royalties Ownership percentage Total purchase price Debt instrument periodic payment Option acquire remaining percentage Outstanding shares additional amount Investor purchase of shares percentage description Purchase of common stock up to the commitment amount Investments Advanced to the investor Percentage of common stock issued and outstanding Number of shares issued, value Exchangeable shares Gain (Loss) from Litigation Settlement Monthly consulting fee Cash Due from related party Sales tax receivable Prepaid expenses Trade name Developed technology Legal and compliance framework Goodwill Total assets acquired Accounts payable and accrued expenses Total liabilities assumed Net assets acquired Revenue Net loss Business Combination [Table] Business Combination [Line Items] Business acquisition, date Exchangeable shares per purchased share Business acquisition, payment Exchangeable shares issued, value Assumed liabilities Acquisition related costs Finite lived intangible assets Royalty rate Discount rate Estimated useful lives Fair value of goodwill Goodwill Amortization of Intangible Assets [custom:AccruedFindersFees-0] Severance expenses Acquisitions value Acquisitions shares Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Legal and compliance framework Goodwill Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Range (Weighted Average) Tax amortization period Initial recognition (May 28, 2025) Change in fair value Settlements (Exchange to Common Stock) Balance Fair value exchangeable shares amount Reaffirmed discount rate Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Revenues Research and development - stock-based compensation expenses General and administrative - stock-based compensation expenses Total operating and segment expense Interest income (expense) Gain on settlement and extinguishment of debt Other income (expense) Related Party Transaction [Table] Related Party Transaction [Line Items] Other liabilities Subsequent Event [Table] Subsequent Event [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Aaggregate principal amount Additional convertible debt Sale of stock issued, vale Variable weighted average percentage, description Sale of stock per share Commitment fee description Shares price Public offering value Sales tax receivable. Series C 9% Convertible Preferred Stock [Member] GainLossOnSettlementAndForgivenessOfAccountsPayable Stock issued during period value sale of common stock and warrants Stock issued during period shares sale of common stock and warrants. Stock issued during period value sale of extinguishment of debt. Stock issued during period shares sale of extinguishment of debt. Accretion of deemed preferred stock dividend. Deemed preferred stock dividend. Stock issued during period value other one. Stock issued during period shares other one. Change in fair value of derivative liability. Stock issued during period value as forgiveness of accounts payable Stock issued during period shares as forgiveness of accounts payable Dividend payable on preferred stock charged to additional paid in capital. Common stock issued in settlement of debt. Common stock issued for conversion of note payable and accrued interest Recognition of derivative liability as part of business combination noncash Viral Clear[Member] BioSig AI Sciences, Inc. [Member] Working captal deficit Customer One [Member] Customer Two [Member] Customer Three [Member] Revenue and Accounts Receivable [Policy Text Block] Exchangeable Shares [Member] Allowance for credit losses on accounts receivable. Common stock issued for services rendered. Increase decrease in sales tax receivable. Sale of common stockunder at the market offering net of transaction costs. Right to use Asset [Table Text Block] Operating lease right to use assets gross. Operating lease right to use asset accumulated depreciation. Lessor sales type lease discount rate. Contract Assets Current [Member] Contract Assets Noncurrent [Member] Sales type lease invoiced to customer. 2023 Long-Term Incentive Plan [Member] Options Under 9.99 [Member] Options 10.00 To 19.99 [Member] Options 20.00 To 49.99 [Member] Options 50.00 To 69.99 [Member] Accrued reimbursements current. Accrued consulting current. Accrued research and development expenses. Accrued office expense and other expense. Weighted average remaining contractual term options outstanding. Accrued settlement expense. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants, Weighted Average Remaining Contractual Term Measurement Input Dividend Payout [Member] Schedule of Warrants or Rights Shares Authorized Exercise Price Range [Table Text Block] Warrants At 0.3000 [Member] Warrants At 0.9547 [Member] Warrants At 17800 [Member] Warrants At 23875 [Member] Warrants At 33640 [Member] Warrants At 40660 [Member] Warrants At 44550 [Member] Warrants At 44660 [Member] Warrants At 46626 [Member] Warrants At 49252 [Member] Warrants At 49290 [Member] Warrants At 51358 [Member] Warrants At 71810 [Member] Warrants At 75020 [Member] Warrants At 79630 [Member] Warrants At 90000 [Member] Warrants At 95960 [Member] Warrants At 100992 [Member] Warrants At 102600 [Member] Warrants At 104678 [Member] Warrants At 113000 [Member] Warrants At 132800 [Member] Warrants At 140000 [Member] Warrants At 480000 [Member] Warrants At 616000 [Member] Warrants expiration date description. Shares issued for cashless exercise of warrants. Class of warrants or right issued. Class of warrants or right forfeited. Class of warrantsr or right expried. Class of warrant or rights vested and expected to vest outstanding. Class of warrant or rights exercisable. Class of warrant or right exercise price of warrants or rights issued. Class of warrant or right exercise price of warrants or rights expired. Class of warrant or rights weighted average exercise price of warrants or rights outstanding. Class of warrant or rights weighted average exercise price of warrants or rights vested and expected to vest outstanding. Class of warrant or rights weighted average exercise price of warrants or rights exercisable. Warrants granted weighted average remaining contractual term. Warrants weighted average remaining contractual term issued. Warrants outstanding weighted average remaining contractual term. Warrants vested and expected to vest outstanding weighted average remaining contractual term. Warrants exercisable weighted average remaining contractual term. Class of warrant or rights outstanding intrinsic value. Share based compensation arrangement by share based payment award options exercised intrinsic value. Class of warrant or rights vested and expected to vest outstanding intrinsic value. Class of warrant or rights exercisable intrinsic value. Share based compensation arrangement by share based payment award options expired intrinsic value Purchase price of warrants. Key Consultant [Member] Purchase Agreement [Member] Class of warrant or rights granted. H.C Wainwright And Co LLC [Member] Sales Agreement [Member] Market Offering Agreement [Member] 2019 Long-Term Incentive Plan [Member] ViralClear Pharmaceuticals, Inc. [Member] Class of warrant or rights weighted average exercise price of warrants or rights expired. Range One [Member] Share based compensation arrangement by share based payment award equity instruments other than options vested number of shares. Share based compensation arrangement by share based payment award equity instruments other than options unvested number of shares. Share based compensation arrangement by share based payment award equity instruments other than options vested and unvested number of shares. Legal and Compliance Frame Work [Member] BioSig AI Sciences, Inc. [Member] Schedule of NonControlling Interest [Table Text Block] Net Income (Loss) Average noncontrolling interest percentage of profit losses. Finite lived intangible assets amortization expense after year four. One Customer [Member] Royalty percentage of net sales. Twenty Twenty Seventeen Know How License Agreement [Member] EP Software Agreement [Member] Tools Agreement [Member] Viral Clear Patent Agreement [Member] Trek Therapeutics [Member] First Country [Member] Second Country [Member] TriView Capital Ltd [Member] Subscription Agreement [Member] Investor purchase of shares percentage description. Purchase of common stock shares up to commitment amount. Advanced to investor. Streamex Exchange Corporation [Member] Share Purchase Agreement [Member] Payments for accrued. Settlement Agreement [Member] Business combination recognized identifiable assets acquired and liabilities assumed due from related party Business combination recognized identifiable assets acquired and liabilities assumed sales tax receivable. Business combination recognized identifiable assets acquired and liabilities assumed trade name. Business combination recognized identifiable assets acquired and liabilities assumed developed technology. Business combination recognized identifiable assets acquired and liabilities assumed legal and compliance framework. Business combination recognized identifiable assets acquired and liabilities assumed goodwill. Royalty rate. Discount rate. Securitization Platform [Member] Blockchain Integration [Member] Developed Technology [Member] Research and development stock based compensation expenses. General and administrative stock based compensation expenses. Mr Amato [Member] Senior Secured Convertible Debentures [Member] Trade Name [Member] Royalty Rate [Member] Relief from Royalty Method [Member] Earnings Before Interest and Taxes [Member] Discount Rate [Member] Income Tax Rate [Member] Tax Amortization Period [Member] Multi Period Excess Earnings Method [Member] Replacement Cost Growth Rate [Member] After Tax Rate of Return [Member] Useful Life [Member] Cost Approach [Member] Terminal Growth Rate [Member] Capitalization Rate [Member] Fair value exchangeable shares amount. Settlements exchange to common stock. Reaffirmed discount rate. Standby Equity Purchase Agreement [Member] Business combination recognized identifiable assets acquired and liabilities assumed. Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable and accrued expenses. Investors [Member] Testing and Demo Equipment [Member] Stock issued during period value common stock cancelled Stock issued during period shares common stock cancelled Settlement and extinguishment of accounts payable Stock issued during period shares cancelled Increase decrease inunbilled revenue Cash held in deposits. Share based compensation arrangement by share based payment award options vested in period fair values. Recognition of assets acquired as part of business combination (non-cash). Recognition of liabilities assumed as part of business combination (non-cash). Two Secured Convertible Debentures [Member] Accrued finders fees. Concentration of Assets [Policy Text Block] Consolidated asset percentage. Other comprehensive income. BioSig AI Sciences, Inc. [Member] [Default Label] Assets, Current Assets, Noncurrent Liabilities, Current Liabilities Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Net Income (Loss) Attributable to Parent Dividends, Preferred Stock Preferred Stock Dividends, Income Statement Impact Net Income (Loss) Available to Common Stockholders, Basic Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings Deemed preferred stock dividend StockIssuedDuringPeriodValueOtherOne StockIssuedDuringPeriodSharesOtherOne CommonStockIssuedForServicesRendered Share-Based Payment Arrangement, Expense AllowanceForCreditLossesOnAccountsReceivable Increase (Decrease) in Accounts Receivable Increase (Decrease) in Leasing Receivables IncreaseDecreaseInSalesTaxReceivable Increase (Decrease) in Other Receivables Increase (Decrease) in Prepaid Expense Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Businesses, Net of Cash Acquired Cash Provided by (Used in) Investing Activity, Including Discontinued Operation SaleOfCommonStockUnderAttheMarketOfferingNetOfTransactionCosts Proceeds from Other Equity Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Cash Equivalents, at Carrying Value Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Operating lease right to use asset accumulated depreciation Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss Dividends Payable Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Class of warrant or rights outstanding intrinsic value Class of warrants or right issued WarrantsWeightedAverageRemainingContractualTermIssued ClassOfWarrantsOrRightForfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Class of warrant or rights weighted average exercise price of warrants or rights outstanding Warrants outstanding weighted average remaining contractual term Class of warrant or rights vested and expected to vest outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding Class of warrant or rights exercisable ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumberOfShares ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnvestedNumberOfShares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValues Derivative Liability, Measurement Input Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromRelatedParty BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSalesTaxReceivable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill Business Combination, Recognized Asset Acquired, Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses Business Combination, Recognized Liability Assumed, Liability Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Business Combination, Pro Forma Information, Pro Forma Revenue Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax Finite-Lived Intangible Assets, Fair Value Disclosure Goodwill, Fair Value Disclosure Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs